neurological research News
-
National Hospitals Network of Japan
Dr Steven Chance, Chief Executive Officer, is invited back to Japan by NHO Neurology Research Group to speak on the role of CDM as a potential clinical tool for the detection of ...
-
Newronika Raises an 8.4M EUR Series-A Round
Newronika, a spin-off of world-class neurological research centers Policlinico of Milan and University of Milan, has raised an 8.4 million Euros Series-A round. The investment was led by French venture capital fund Omnes together with existing investors Innogest Capital and Indaco Venture Partners SGR ("Indaco SGR") on behalf of Indaco Ventures I and Atlante Ventures funds. F3F and an undisclosed ...
-
Private: BBC News - ‘Weight loss headset’ developed by NI man is showcased in US
The product, Modius, claims to stimulate the part of the brain that controls fat storage and metabolism. The company, Modius Health, was set up by neuroscientist Dr Jason McKeown from Portglenone, County Antrim in 2013. Modius has made the top 10 in the Last Gadget Standing awards at the Consumer Electronics Show (CES) in Las Vegas. The winning gadget will be decided by vote on Thursday. ...
-
Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design today announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling ...
By Iktos
-
Brain Sentinel, Inc. Announces the Purchase of IctalCare A/S Assets
Brain Sentinel, Inc., a Texas company, has purchased the assets of IctalCare A/S, a Danish company. These assets include intellectual property, and a non-prescription, wearable device designed to monitor for seizure activity. "We are excited to add to our product line a small, wearable surface electromyography (sEMG) monitor that consumers may order and use without a prescription," said Mike ...
-
Healx launches AI-powered indication expansion partnership with Ono Pharmaceutical Co. Ltd.
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology ...
By Healx Ltd.
-
People with Parkinson’s disease may have double the risk for melanoma, a dangerous skin cancer
An analysis of several studies shows that people with Parkinson’s disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases. The research is published in the June 7, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. Parkinson’s disease is a brain disorder ...
-
Creative Proteomics Launches Crotonylation Proteomics Analysis Service to Enhance Your Epigenetic Research
Creative Proteomics, a leading provider of proteomics, metabolomics, and bioinformatics services, is pleased to announce the launch of its new Crotonylation Proteomics Analysis Service. This service is designed to provide researchers with a comprehensive and in-depth analysis of crotonylation, a newly discovered post-translational modification (PTM) of lysine residues. Crotonylation, a recently ...
-
First Patient Enrolled in BrainQ`s Pivotal Trial, EMAGINE, for Frequency-Tuned Electromagnetic Field Therapy to Reduce Disability Following Ischemic Stroke
WASHINGTON, Dec. 9, 2021 – BrainQ today announced that the first patient has been enrolled at MedStar National Rehabilitation Hospital in its pivotal, randomized, double-blind, multicenter trial, EMAGINE (the BQ5 Study). The trial is evaluating its frequency-tuned electromagnetic field treatment in facilitating recovery in individuals with moderately-severe ischemic stroke. The EMAGINE ...
-
Healx and Ovid Therapeutics Enter Strategic Partnership
Ovid Therapeutics (NASDAQ:OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, and Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced that Healx has secured from Ovid an exclusive option to license rights to develop and ...
By Healx Ltd.
-
Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
-
Confo Therapeutics Establishes Medical Advisory Board
Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The international MAB members contribute ...
-
NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology. In test ...
-
Breakthrough Israeli stroke therapy technology BrainQ announces a $40M funding round
Funding round led by Hanaco Ventures, joined by Dexcel Pharma and Peregrine Ventures, and existing investors. BrainQ’s investigational neurorecovery technology has been granted FDA Breakthrough Device Designation, and is set to be trialed in a multicenter pivotal study for stroke patients in select hospitals across the US. Jerusalem, Israel – August 16, 2021 – Israeli ...
-
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC: HMTXF; FRA:2VFO) is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer. Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is ...
-
People with Parkinson’s Disease may have double the risk for Melanoma, a dangerous skin cancer
An analysis of several studies shows that people with Parkinson’s disease have a significantly higher risk of melanoma, the most dangerous type of skin cancer and the leading cause of death from skin diseases. The research is published in the June 7, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology. Parkinson’s disease is a brain disorder ...
-
Creative Proteomics Introduces Methionine Cycle Analysis Service for Metabolomics Research
Creative Proteomics, a leading provider of advanced proteomics and metabolomics services, is proud to announce the launch of its innovative Methionine Cycle Analysis Service. This service represents a significant leap forward in the field of metabolomics, providing researchers with a powerful tool to unravel the complexities of metabolic pathways. Methionine, a pivotal amino acid, is central to ...
-
Brain Sentinel Announces Satellite Symposium at AES Annual Meeting in Baltimore, Maryland
Brain Sentinel, Inc. announces it is hosting a non-CME satellite symposium for healthcare professionals in Baltimore, Maryland at the AES Annual Meeting. The symposium, “Fundamentals of Quantitative Surface Electromyography (sEMG) for Long-Term Monitoring”, has 5 key learning objectives: Understand methods of quantitative sEMG analysis during ictal events; Review specific sEMG ...
-
Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode for Severe Paralysis
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like material inserted ...
-
Neurona Therapeutics Announces C-Suite Leadership Team
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced three promotions within its leadership team: Catherine Priest, Ph.D., previously Neurona’s vice president of preclinical development, has been appointed to chief development officer, Gautam Banik, Ph.D., formerly Neurona’s ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you